Compass Therapeutics (CMPX) News
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.6882+0.0097 (+1.43%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CMPX news summary
We found 7 recent headlines mentioning Compass Therapeutics (CMPX): 1 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, CMPX is up 1.43% at $0.6882. The most recent story, "Compass Therapeutics, Inc. Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Compass Therapeutics headlines
- Compass Therapeutics, Inc. Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementOn November 19, 2026, Compass Therapeutics, Inc. received a deficiency letter from the Nasdaq Listing Qualifications Department stating that the closing bid price for the company’s common stock…Nasdaq
- Compass Therapeutics, Inc. Reports 2026 Third Quarter Financial Results and Net loss of $27.2 millionCompass Therapeutics, Inc. reported a net loss of $27.2 million, or $0.15 per common share, for the quarter ended September 30, 2026, compared to a net loss of $14.3 million, or $0.08 per common…Nasdaq
- Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate UpdateBOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…GlobeNewswire
- Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual MeetingBOSTON, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…GlobeNewswire
- Compass Therapeutics to Participate in Upcoming November Investor EventsBOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…GlobeNewswire
- Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…GlobeNewswire
- Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…GlobeNewswire